As Predicted, Stage 4 Prostate Cancer Diagnoses Have Increased Markedly

JAMA Network Open published an article showing that, after the US Preventive Services Task Force (USPSTF) recommended stopping “routine” early-detection screening with prostate-specific antigen (PSA), the incidence of metastatic prostate cancer (the annual number of newly diagnosed patients) in the US rose rapidly over the years. This was an outcome many prostate cancer specialists had predicted.
In the US, PSA screening for prostate cancer first began in 2008 for men older than 75 and continued for all men in 2012. It was then thought that the harms of screening all men (leading to unnecessary biopsies, prostatectomies [surgical removal of the prostate] and other treatments in many men) outweighed the benefit of detecting high-risk disease early in a few men. However, prostate cancer specialists warned that stopping routine PSA screening would reduce overdiagnosis and treatment but have the unfortunate consequence of failing to detect cases that would eventually spread.
For this study, researchers at the University of Southern California in Los Angeles analyzed the incidence of metastatic prostate cancer (mPK) in the Surveillance, Epidemiology, and End Results (SEER) database between 2004 – 2018 (using the latest available data in 2018). SEER covered approximately 28% of the US population, and almost 50 thousand new mPK (metastatic prostate cancer) cases were recorded over the period.
Among men aged 45-75, mPK incidence from the time the USPSTF changed its screening recommendations until 2018 increased by 41%, corresponding to an annual percentage change (YYD) of 5.3%. Among men aged 75 and older, the mPK rate increased by 43% through 2018 (YYD 6.5%).
Researchers did not observe an increase in prostate cancer-related deaths, but given the average survival of 5-7 years, it may be too early to say.
The researchers, led by Mihir Desai, Professor of Clinical Urology at the University of Southern California, said, “Observing an increase in mPK incidence does not mean that screening practices should change. The overall risks versus benefits of PSA-based screening are extremely complex, and various other factors affecting population health must also be considered”.
But screening practices have already changed. Richard Hoffman, Professor of Internal Medicine at the University of Iowa in Iowa City, said that in 2018 the USPSTF withdrew its opposition to screening and instead recommended individualized decision-making for men aged 55-69, citing new evidence that screening prevents metastatic disease and reduces prostate cancer mortality (death rates) more than previously understood.
Hoffman says “trends in mPK will change temporarily because screening guidelines have changed” . Hoffman also said that, for now, doctors should consistently discuss screening with men who are “healthy enough to benefit” from detecting dangerous tumors early, and to strike the right balance between minimizing overdiagnosis and catching high-risk tumors before they spread, they should “consult one another for shared decision-making”. Easier said than done, but the field is developing. Hoffman noted that, for tumors that appear to be low-risk, active surveillance instead of surgery was a step in the right direction.
*
- You may be interested in: The Hidden Cost of Prostate Cancer Surgery: Patient Regret
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.